Physician profile
Samer Ilayan
NPI 1174183586
$2,110.13
in general payments reported to CMS, 2019-2025
12 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.27 · 2023: $381 · 2024: $935 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $678.45 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $316.21 | 2023-2025 | |
| Abbvie INC. | $295.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.13 | 2023-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $163.08 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $141.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $135.96 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $69.15 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $57.95 | 2023-2024 | Prolia, Evenity, Repatha |
| Dexcom, INC. | $39.75 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $33.22 | 2024 | Voquezna |
| Tolmar, INC. | $13.53 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Ilayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.